middle.news
Arovella Advances with IND Filing for Pioneering CAR-iNKT Therapy
12:41pm on Tuesday 30th of December, 2025 AEDT
•
Biotechnology
Read Story
Arovella Advances with IND Filing for Pioneering CAR-iNKT Therapy
12:41pm on Tuesday 30th of December, 2025 AEDT
Key Points
IND application submitted to U.S. FDA for ALA-101
First-in-human Phase 1 trial planned for CD19-positive blood cancers
Off-the-shelf allogeneic CAR-iNKT therapy offers scalable manufacturing
FDA clearance enables clinical trials in Australia and the U.S.
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE